Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET

The Massachusetts General Hospital Radiochemistry Program, in collaboration with Pfizer, has developed unique (11)C and (18)F-labeling strategies to synthesize isotopologs of lorlatinib (PF-06463922) which is undergoing phase III clinical trial investigations for treatment of non-small-cell lung can...

Descripción completa

Detalles Bibliográficos
Autores principales: Collier, T. Lee, Maresca, Kevin P., Normandin, Marc D., Richardson, Paul, McCarthy, Timothy J., Liang, Steven H., Waterhouse, Rikki N., Vasdev, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661750/
https://www.ncbi.nlm.nih.gov/pubmed/29067878
http://dx.doi.org/10.1177/1536012117736669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661750/
https://www.ncbi.nlm.nih.gov/pubmed/29067878
http://dx.doi.org/10.1177/1536012117736669

Ejemplares similares